; (E) (i) research and development of innovations that shift the lifecycle of medical supplies and devices from single use to sustainable, circular economies, including low-environmental impact sterilization techniques; and (ii) support of public-private partnerships that enable scientific translation of those innovations; (F) the development of clinically equivalent and improved, low-climate-footprint interventions and pharmaceuticals and the study of the environmental impacts of those interventions and pharmaceuticals to enable high-quality, environmentally conscious clinical decision making; and (G) conducting and supporting research, development, demonstration, and commercial application of renewable energy technologies and strategies to meet the energy demand and energy security needs of infrastructure critical to health care. (d) Termination The Initiative shall terminate on December 31, 2033. 399OO–1. Interagency coordination (a) In general Not later than 1 year after the date of enactment of the Green New Deal for Health Act , the President shall establish an interagency committee (referred to in this part as the Interagency Committee ), to coordinate the Initiative, as appropriate, among the departments, offices, and agencies described in subsection (b)(1). (b) Membership (1) In general The membership of the Interagency Committee shall consist of— (A) 3 representatives of the Department of Health and Human Services, which shall include— (i) 1 representative of the Office of Climate Change and Health Equity; and (ii) 1 representative of the National Institutes of Health; (B) 1 representative of the Office of Science and Technology Policy; (C) 1 representative of the National Science Foundation; (D) 1 representative of the Environmental Protection Agency; (E) 1 representative of the Department of Energy; (F) 1 representative of the Department of Housing and Urban Development